Private equity fundraising struggled in 2024, with total capital raised declining for the third consecutive year. Read more ...
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback